As The Stock Falls By -22.39% Year-To-Date, Celldex Therapeutics Inc. (NASDAQ: CLDX)’S Stock Continues To Progress In 2022 – Marketing Sentinel
Home  »  Science   »  As The Stock Falls By -22.39% Year-To-Date, Cellde...

As The Stock Falls By -22.39% Year-To-Date, Celldex Therapeutics Inc. (NASDAQ: CLDX)’S Stock Continues To Progress In 2022

During the last session, Celldex Therapeutics Inc. (NASDAQ:CLDX)’s traded shares were 0.43 million, with the beta value of the company hitting 2.66. At the end of the trading day, the stock’s price was $29.99, reflecting an intraday gain of 7.03% or $1.97. The 52-week high for the CLDX share is $57.20, that puts it down -90.73 from that peak though still a striking 18.61% gain since the share price plummeted to a 52-week low of $24.41. The company’s market capitalization is $1.48B, and the average intraday trading volume over the past 10 days was 0.7 million shares, and the average trade volume was 563.73K shares over the past three months.

Celldex Therapeutics Inc. (CLDX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.50. CLDX has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.42.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Celldex Therapeutics Inc. (NASDAQ:CLDX) trade information

Celldex Therapeutics Inc. (CLDX) registered a 7.03% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.03% in intraday trading to $29.99 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is 4.02%, and it has moved by -15.59% in 30 days. Based on these gigs, the overall price performance for the year is 10.71%. The short interest in Celldex Therapeutics Inc. (NASDAQ:CLDX) is 5.2 million shares and it means that shorts have 8.79 day(s) to cover.

The consensus price target of analysts on Wall Street is $64.83, which implies an increase of 53.74% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $59.00 and $68.00 respectively. As a result, CLDX is trading at a discount of -126.74% off the target high and -96.73% off the low.

Celldex Therapeutics Inc. (CLDX) estimates and forecasts

Statistics show that Celldex Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Celldex Therapeutics Inc. (CLDX) shares have gone down -32.45% during the last six months, with a year-to-date growth rate less than the industry average at -22.56% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -16.70% this quarter and then jump 25.50% in the quarter after that. In the rating firms’ projections, revenue will decrease -28.00% compared to the previous financial year.

Revenue for the current quarter is expected to be $1.04 million as predicted by 5 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $650k by the end of Mar 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $3.79 million and $685k respectively. In this case, analysts expect current quarter sales to shrink by -72.50% and then drop by -5.10% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 38.70%. While earnings are projected to return 18.40% in 2022.

CLDX Dividends

Celldex Therapeutics Inc. is due to release its next quarterly earnings between March 28 and April 01. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Celldex Therapeutics Inc. (NASDAQ:CLDX)’s Major holders

Celldex Therapeutics Inc. insiders own 0.21% of total outstanding shares while institutional holders control 100.95%, with the float percentage being 101.16%. FMR, LLC is the largest shareholder of the company, while 261 institutions own stock in it. As of Dec 30, 2021, the company held over 7.0 million shares (or 14.98% of all shares), a total value of $270.46 million in shares.

The next largest institutional holding, with 3.92 million shares, is of RTW Investments LP’s that is approximately 8.39% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $151.53 million.

Also, the Mutual Funds coming in first place with the largest holdings of Celldex Therapeutics Inc. (CLDX) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Dec 30, 2021 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 1.5 million shares. This amounts to just over 3.21 percent of the company’s overall shares, with a $58.05 million market value. The same data shows that the other fund manager holds slightly less at 1.33 million, or about 2.84% of the stock, which is worth about $51.35 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts